A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Adoption of Sight-saving Sleep Mask Could Save the NHS Millions

A pioneering treatment to prevent blindness in people suffering from diabetic retinopathy is set to benefit NHS patients for the first time, following the adoption of PolyPhotonix’s Noctura 400 sleep mask by Ashford and St Peter’s NHS Foundation Trust. Shown to improve patients’ visual acuity,the mask could potentially save the health service millions of pounds a year.

Backed by the RENDER Study, the innovative sleep mask has demonstrated improvement and stabilisation of diabetic eye disease in 96% of patients.1 It is an early stage non-invasive alternative to current, later-stage invasive treatments such as eye injections for patients with the condition; which is a leading cause of blindness in Europe.3

Based on research undertaken by Ashford and St Peter’s NHS Foundation Trust, improving patient outcomes with an earlier stage intervention could save the NHS £3,000 per patient. It is believed that the sleep mask could deliver cost savings estimated in excess of £180m per year if adopted across the NHS.2

Moreover, it could ease pressure on NHS services by reducing hospital clinic appointments and the use of eye injection treatments at a later stage. Diabetes is a major health crisis facing the UK and costs the NHS around £10bn a year,4 most of which goes in treating complications, including eyesight damage.

The current NHS pathway involves monitoring patients with early signs of diabetic retinopathy until their eyes deteriorate and they qualify for treatment intervention. However, the Noctura 400 sleep mask uses intervention at an early stage to prevent future problems before they start.

The sleep mask treatment can be worn during normal hours of sleep and can prevent the need for expensive and time intensive injections directly into the eyeball, which can be stressful and unpleasant for patients, and comes with a risk of side effects.1

Michelangelo Biasiucci, 64, from London, is one patient whose life has been transformed by using the sleep mask. He said:

“After being referred to the hospital by my GP, I was diagnosed with diabetic retinopathy. Part of my treatment for this was to have injections in my eyes, and looking back, I don’t know how I tolerated them!

“I was relieved that not so long after, my consultant prescribed the mask. I would say that the mask has given me my life back – not only can I see so much clearer, but it has enabled me to carry out my job safely again. As a driver, I can now work safely again, especially at night, thanks to the mask.”

The mask maintains or improves patient’s vision and the physiological effects of diabetes on their eyes by delivering a precise level of light at a particular wavelength during a patient’s normal hours of sleep in a home-based setting. Noctura 400 administers low-level light to prevent the eyes’ increased demand of oxygen at night and reduces the damaging effects of diabetic retinopathy on patients’ eyesight.

Commenting on the treatment’s benefits Mr Ulrich Meyer-Bothling, Consultant Ophthalmic Surgeon at Ashford and St Peter’s Hospitals NHS Foundation Trust, said:

“The Trust’s decision to offer the sleep mask as part of its diabetic retinopathy pathway is great news for patients and the NHS alike.

“For patients, it represents a pain-free treatment option for their condition. It is non-invasive, and they are, in effect, treated whilst they sleep. It also doesn’t require patients to attend the hospital as frequently, giving them more of their time back. It represents a gentler approach to treating or even preventing diabetic retinopathy and diabetic macular oedema. I’m proud that most of the patients I have treated with the mask have shown stabilisation and improvement in their diabetic eye disease.”

Richard Kirk, Chief Executive of PolyPhotonix, said:

“For the NHS, treating diabetic retinopathy patients with the Noctura 400 sleep mask represents a cost-effective alternative to existing treatments. At a time when our healthcare budgets are already stretched, adding the sleep mask to existing care pathways makes sound financial sense in helping healthcare services recover from the pandemic and freeing up hospital appointments for those in greater need of emergency care.

He concluded, Most importantly, it prevents problems before they arise and enables doctors to improve patient care.”


  1. Meyer-Bothling U, Meyer-Bothling O, Pinney M. A Real-World Single-Centre Study of Patients with Diabetic Macular Oedema Who Wore a Home-Use Sleep Mask (Noctura 400) for One Year. Journal of Ophthalmology. 2021. –> Meyer-Bothling U, Meyer-Bothling O, Pinney M. A Real-World Single-Centre Study of Patients with Diabetic Macular Oedema Who Wore a Home-Use Sleep Mask (Noctura 400) for One Year. Journal of Ophthalmology. 2021;2021:6612126
  2. PolyPhotonix Data on File. 2021.
  3. Hristova E, Koseva D, Zlatarova Z, Dokova K. Diabetic Retinopathy Screening and Registration in Europe-Narrative Review. Healthcare (Basel). 2021;9(6): 745.
  4. NHS England. NHS Prevention Programme cuts chances of Type 2 diabetes for thousands. 2022. Available from: www.england.nhs.uk/2022/03/nhs-prevention-programme-cuts-chances-of-type-2-diabetes-for-thousands/#:~:text=Evidence%20has%20shown%20that%20the,effective%20in%20the%20long-term. Accessed October 2022.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Sachita Shah, Sr. Director, Global Health, Butterfly Network, "Butterfly is proud to continue improving maternal health equity through Phase Two of the largest-scale handheld ultrasound distribution and training ever conducted in Sub-Saharan Africa. South Africa is an emerging market that continues to have disproportionately high rates of maternal mortality and stillbirth. Patients need easier access to antenatal imaging, and clinicians need better capabilities for screening high-risk conditions that lead to disproportionately worse pregnancy outcomes in rural areas in the public sector. Together with CHAI and GUSI, we can tackle this by making ultrasound much more accessible, so high-risk conditions can be identified earlier in care, which is known to improve outcomes.”
The clinical Study will enroll up to 97 patients at up to 12 European investigational sites. Completion of the study is expected this year, and results will support CE mark and pre-market approval submissions reports Vivasure Medical.
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.

By using this website you agree to accept Medical Device News Magazine Privacy Policy